Allogene Therapeutics
ALLO
169 hedge funds and large institutions have $2.26B invested in Allogene Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 55 reducing their positions, and 30 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0.87% more ownership
Funds ownership: 61% → 61.87% (+0.87%)
0% more capital invested
Capital invested by funds: $2.25B → $2.26B (+$10.6M)
2% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 55
7% less funds holding
Funds holding: 182 → 169 (-13)
40% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 30
48% less call options, than puts
Call options by funds: $2.18M | Put options by funds: $4.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$20.8M |
| 2 |
JP Morgan Chase
New York
|
+$19.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.1M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$18.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$11.9M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$9.37M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$8.48M |
| 5 |
Millennium Management
New York
|
-$6.57M |
ALLO Hedge Fund Activity: Q3 2021 in Review
169 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2021, worth a combined $2.26B — up 0.47% from $2.25B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ALLO and 18 opened new positions — a net loss of 12 holders — while 55 trimmed existing stakes and 54 added.
The largest buyer was Casdin Capital, adding an estimated $20.8M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $18.4M sold.
- 169 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2021, down from 182 in Q2 2021.
- Funds reported $2.26B of Allogene Therapeutics stock for Q3 2021, up 0.47% quarter-over-quarter.
- 18 funds opened new Allogene Therapeutics positions in Q3 2021 and 30 closed out, a net change of -12 holders.
- The largest Allogene Therapeutics buyer in Q3 2021 was Casdin Capital, an estimated $20.8M added.
- The largest Allogene Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $18.4M sold.
Based on aggregated 13F filings for Q3 2021.